Objective assessment of tear film in blepharospasm, facial hemispam and aberrant regeneration with periocular botulinum toxin-A.

IF 1.4 4区医学 Q3 OPHTHALMOLOGY

European Journal of Ophthalmology Pub Date : 2025-03-01 Epub Date: 2024-07-26 DOI:10.1177/11206721241266008

Alicia Galindo-Ferreiro, Marta Fraile García, Silvana Schellini, Hortensia Sanchez-Tocino

{"title":"Objective assessment of tear film in blepharospasm, facial hemispam and aberrant regeneration with periocular botulinum toxin-A.","authors":"Alicia Galindo-Ferreiro, Marta Fraile García, Silvana Schellini, Hortensia Sanchez-Tocino","doi":"10.1177/11206721241266008","DOIUrl":null,"url":null,"abstract":"Purpose: Study the effect on the tear film in blepharospasm (BEB), facial hemispasm (FH), or aberrant regeneration (AR) treated with Botulinum Toxin (BTX-A).Methods: A prospective study was used to evaluate the tear film in patients with BEB, FH, or AR treated with BTX-A. Schirmer tests, break-up time (BUT), optical coherence tomography (OCT) meniscus measurement, the Ocular Surface Disease Index (OSDI) questionnaire, and Oxford scale were documented before; 1 month after; and 3 months after BTX-A treatment. Comparisons were made with the Friedman test and Wilcoxon matched-pairs signed rank test was used. A p-value <0.05 was considered statistically significant.Results: A total of 35 eyes from 27 patients were included. The mean patient age was 66.81 ± 12.94 years and 18 (66.7%) were female. Ten (37%) patients had BEB, six (22.2%) had FH, and 11 (40.74%) had AR. BTX-A improved the lid spasms. One month after BTX-A, Schirmer tests showed slight increments (Schirmer 1 p = 0.009; Schirmer 2 p = 0.05) and at 3 months they became similar to pre-treatment (p = 0.5). The BUT test was not significantly different at 1 month (p = 0.450) or at 3 months. On OCT 1 month after BTX-A, there was an increase in tear meniscus area (p = 0.004), height (p = 0.007), and depth (p = 0.004), and at 3 months the measurements also became similar to the pre-BTX-A values. No significant changes in the OSDI (p = 0.717) and Oxford scale (p = 0.255).Conclusion: OCT is a good tool to detect the increase in tear meniscus after periocular BTX-A in BEB, FH, and AR.","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"722-726"},"PeriodicalIF":1.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721241266008","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Study the effect on the tear film in blepharospasm (BEB), facial hemispasm (FH), or aberrant regeneration (AR) treated with Botulinum Toxin (BTX-A).

Methods: A prospective study was used to evaluate the tear film in patients with BEB, FH, or AR treated with BTX-A. Schirmer tests, break-up time (BUT), optical coherence tomography (OCT) meniscus measurement, the Ocular Surface Disease Index (OSDI) questionnaire, and Oxford scale were documented before; 1 month after; and 3 months after BTX-A treatment. Comparisons were made with the Friedman test and Wilcoxon matched-pairs signed rank test was used. A p-value <0.05 was considered statistically significant.

Results: A total of 35 eyes from 27 patients were included. The mean patient age was 66.81 ± 12.94 years and 18 (66.7%) were female. Ten (37%) patients had BEB, six (22.2%) had FH, and 11 (40.74%) had AR. BTX-A improved the lid spasms. One month after BTX-A, Schirmer tests showed slight increments (Schirmer 1 p = 0.009; Schirmer 2 p = 0.05) and at 3 months they became similar to pre-treatment (p = 0.5). The BUT test was not significantly different at 1 month (p = 0.450) or at 3 months. On OCT 1 month after BTX-A, there was an increase in tear meniscus area (p = 0.004), height (p = 0.007), and depth (p = 0.004), and at 3 months the measurements also became similar to the pre-BTX-A values. No significant changes in the OSDI (p = 0.717) and Oxford scale (p = 0.255).

Conclusion: OCT is a good tool to detect the increase in tear meniscus after periocular BTX-A in BEB, FH, and AR.

查看原文本刊更多论文

用眼周肉毒杆菌毒素 A 客观评估眼睑痉挛、面部半球和异常再生的泪膜。

目的：研究使用肉毒杆菌毒素（BTX-A）治疗眼睑痉挛（BEB）、面部半球痉挛（FH）或异常再生（AR）对泪膜的影响：方法：采用前瞻性研究对接受 BTX-A 治疗的 BEB、FH 或 AR 患者的泪膜进行评估。记录了BTX-A治疗前、治疗后1个月和治疗后3个月的施尔默试验、泪液破裂时间（BUT）、光学相干断层扫描（OCT）半月板测量、眼表疾病指数（OSDI）问卷和牛津量表。比较采用弗里德曼检验和 Wilcoxon 配对符号秩检验。A p 值结果：共纳入 27 名患者的 35 只眼睛。患者平均年龄为（66.81 ± 12.94）岁，18 名患者（66.7%）为女性。10名患者（37%）患有BEB，6名患者（22.2%）患有FH，11名患者（40.74%）患有AR。BTX-A 改善了睑痉挛。BTX-A 一个月后，Schirmer 测试显示略有增加（Schirmer 1 p = 0.009；Schirmer 2 p = 0.05），3 个月后与治疗前相似（p = 0.5）。BUT 测试在 1 个月 (p = 0.450) 或 3 个月时没有明显差异。BTX-A 治疗 1 个月后的 OCT 显示，撕裂半月板的面积（p = 0.004）、高度（p = 0.007）和深度（p = 0.004）均有所增加，3 个月后，这些测量值也与 BTX-A 治疗前的值相似。OSDI（p = 0.717）和牛津量表（p = 0.255）无明显变化：结论：OCT是检测BEB、FH和AR眼周BTX-A后撕裂半月板增加的良好工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Ophthalmology 医学-眼科学

CiteScore

3.60

自引率

0.00%

发文量

372

审稿时长

3-8 weeks

期刊介绍： The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.